CMC consultancy services for biotech & pharma companies

CMC

Our CMC consultancy services support life science companies – pharma, biotech, and medtech – through every stage of product development. From early-phase CMC strategy to regulatory submission support for INDs, CTDs, and Module 3 documentation, we deliver compliant, science-driven solutions tailored to your molecule and market.

Whether you’re developing a novel biologic or small molecule drug, our consultants bring deep regulatory expertise and technical insight to help you meet EMA, FDA and global requirements efficiently.

Regulatory CMC

Technology transfer

FAQ: Global CMC requirements

What are the CMC requirements for EMA regulatory submissions?

In the EU, CMC data is submitted as Module 3 of the Common Technical Document (CTD), the global harmonised standard adopted across the major regulatory regions—including the EU, US, Japan, and many other ICH and non-ICH countries. It must include comprehensive details on:

  • Manufacturing processes and controls
  • Specifications for drug substance and drug product
  • Stability data
  • Container closure systems
  • Batch analysis and validation

The information must demonstrate consistent quality, safety, and efficacy of the medicinal product throughout its lifecycle.

A regulatory affairs consultant ensures your CMC data meets EMA expectations and ICH guidelines, minimising the risk of regulatory queries or delays.

What CMC documentation is required for clinical trial applications (CTAs) in the EU?

For clinical trials, CMC data must be submitted in the Investigational Medicinal Product Dossier (IMPD). It includes:

  • Description of the drug substance and product
  • Manufacturing and control processes
  • Specifications and analytical methods
  • Stability data to justify shelf life

As of 2022, all CTAs must be submitted via the Clinical Trials Information System (CTIS) under the EU Clinical Trials Regulation (CTR).

A regulatory affairs expert can help prepare a compliant IMPD, align it with clinical trial timelines, and manage changes during development.

What are the key CMC differences between EU and FDA submissions?

While both the EMA and FDA follow the CTD structure, notable differences include:

  • Stability requirements: EMA expects longer real-time stability data at the time of MAA submission.
  • Impurity thresholds: Different reporting and qualification limits may apply.
  • Process validation timing: EMA typically expects validation at submission, while FDA may accept post-approval commitments.

A Regulatory Affairs expert can help harmonise global submissions and adapt your CMC data to meet region-specific regulatory expectations.

What is a CMC compliance checklist for EU pharmaceutical submissions?

A robust CMC compliance checklist should cover:

  • GMP compliance and documentation
  • Complete and structured Module 3 (per ICH M4Q)
  • Validated analytical methods and batch data
  • Up-to-date stability studies
  • Quality overall summary (Module 2.3)
  • Justifications for specifications and controls

Early and proactive planning is critical to reduce regulatory pushback and shorten review timelines.

A regulatory affairs consultant can conduct a pre-submission compliance audit and help fill documentation gaps ahead of MAA submission.

FAQ: CMC strategy & common challenges

When should CMC planning start in drug development?

CMC planning should begin as early as preclinical development and evolve in parallel with clinical progress. Early activities include:

  • Defining critical quality attributes (CQAs)
  • Developing a scalable manufacturing process
  • Establishing analytical methods
  • Conducting stability studies for the IMPD

Delaying CMC planning can result in clinical delays, regulatory rejections, or expensive rework later in development.

A regulatory affairs consultant can develop a phase-appropriate CMC roadmap that aligns with your regulatory and clinical milestones.

What are the most common CMC deficiencies in EU marketing authorisation applications?

What are the most common CMC deficiencies in EU marketing authorisation applications?

The most frequent CMC-related deficiencies in MAA submissions to EMA include:

  • Incomplete or inconsistent Module 3 content
  • Insufficient process validation data
  • Inadequate justification for specifications
  • Gaps in stability data to support shelf life
  • Lack of GMP compliance documentation

Such deficiencies can result in major objections during scientific review, delaying or even preventing approval.

A regulatory affairs expert can perform a critical gap analysis of your CMC dossier before submission, preventing costly setbacks during review.

How can a company prepare a robust CMC strategy for EU regulatory approval?

A solid CMC strategy includes:

  • Early definition of quality target product profile (QTPP)
  • Phase-appropriate CMC documentation for each development stage
  • Scalable, validated manufacturing processes
  • Lifecycle planning for changes post-approval
  • Alignment with EMA guidelines and ICH Quality development standards  (e.g., Q8–Q11) ICH Q8–Q11 Guidelines

This strategy should be documented and continuously updated as the product advances.

A regulatory affairs consultant brings cross-functional insights to design and implement a compliant, efficient CMC strategy tailored to EU expectations.

How should CMC changes during clinical development be managed in the EU?

CMC changes (e.g., process updates, site changes, new specifications) during clinical development must be:

  • Documented in updated IMPDs
  • Submitted via the CTIS under EU CTR
  • Assessed for regulatory impact (e.g., substantial vs non-substantial)

Failure to notify or justify changes can jeopardise trial continuity and regulatory compliance.

A Regulatory Affairs expert can assess the regulatory impact of changes and manage timely submissions or amendments under EU CTR requirements.

What is the role of Quality by Design (QbD) in EU CMC strategy?

Quality by Design (QbD) is encouraged (though not mandatory) by the EMA and involves:

  • Designing quality into the process from the outset
  • Identifying critical process parameters (CPPs)
  • Establishing design space and control strategies
  • Enhancing product robustness and lifecycle management

QbD can reduce regulatory burden post-approval and support faster changes through well-defined design space.

A regulatory affairs consultant can help integrate QbD principles into your development plan to support a more flexible, efficient regulatory path.

FAQ: Technology transfer in the EU

What is technology transfer in the pharmaceutical industry?

Technology transfer is the structured process of transferring manufacturing processes, analytical methods, and quality knowledge from one site or organisation to another (e.g., from R&D to GMP manufacturing, or from one CMO to another). It ensures:

  • Consistent product quality
  • Compliance with regulatory expectations
  • Scalable and reproducible manufacturing

It includes both analytical transfer and process transfer, and requires clear documentation, protocols, and risk assessments.

A regulatory affairs consultant ensures the tech transfer is aligned with regulatory requirements and properly documented for submission or inspection readiness.

What are the regulatory requirements for technology transfer in the EU?

While the EMA does not issue a single guideline solely for technology transfer, it expects:

  • Detailed documentation of the transfer plan and outcomes
  • Validation of analytical methods at the receiving site
  • Requalification of equipment (if needed)
  • Demonstration of process comparability
  • Notification or variation submission when the transfer affects regulatory filings (e.g., change in manufacturing site)

Tech transfer must support compliance with GMP and ICH Q10 (Pharmaceutical Quality System).

A regulatory affairs expert helps assess regulatory impact, prepare variation filings, and ensure the transfer is compliant with EU regulatory expectations.

When should a technology transfer trigger a variation submission to EMA?

A variation submission is required when the tech transfer results in changes to:

  • Manufacturing site(s)
  • Process parameters or equipment
  • Specifications or analytical methods
  • Product shelf-life or stability data

These changes are usually classified as Type IA, IB, or Type II variations depending on the impact. Incorrect classification or poor documentation can delay product supply or breach compliance.

A Regulatory Affairs consultant can determine the correct variation type, compile the submission, and liaise with EMA or national authorities on your behalf.

What documentation is needed for successful pharmaceutical technology transfer?

Key documents include:

  • Technology Transfer Protocol (TTP): outlines scope, responsibilities, timelines, and deliverables.
  • Process and analytical method transfer reports
  • Validation plans and reports (e.g., process performance qualification [PPQ])
  • Comparability assessments and risk analyses (e.g., FMEA)
  • Change control documentation

All documentation should comply with GMP and be inspection-ready.

A regulatory affairs consultant ensures all documentation is aligned with current guidelines and ready for regulatory submission or inspection review.

What are the common challenges during technology transfer in life sciences?

Common pitfalls include:

  • Incomplete or poorly defined transfer protocols
  • Gaps in process knowledge between sending and receiving units
  • Insufficient analytical method validation or transfer
  • Lack of regulatory alignment on change management
  • Underestimating timeline or resource requirements

These can lead to product quality issues, regulatory delays, or non-compliance during audits.

A regulatory affairs expert brings cross-functional coordination and regulatory insight to help avoid delays, reduce risk, and ensure a compliant, efficient transfer.

Your contact person

Portrait of Erik Hedner Arex Advisor

Erik Hedner

Staffan Thunell

Founding partner

BSc Economics and BA

Staffan has a long background in entrepreneurship within the life science industry. He has 20+ years experience from posit­ions as Founder, Chair­man, CEO and CFO within medical affairs consulting and small pharma. Previously Staffan worked in executive positions in big pharma and specialty pharma companies.